Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study.
Dorien M C F SluijsmansDaphne C RohrichCalin D PopaBart J F van den BemtPublished in: Journal of clinical medicine (2021)
In this study, the use of either ACEi or ARBs in RA patients had no impact on disease activity as measured by the DAS28-CRP. A trend towards lower bDMARD dosages was observed in ARBs users, but the significance of this finding is still unclear.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- signaling pathway
- patient reported outcomes
- interstitial lung disease
- angiotensin converting enzyme